



Xpovio (selinexor)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA. **URGENT**

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Xpovio (selinexor)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Multiple myeloma <input type="checkbox"/> Diffuse large B-cell lymphoma(DLBCL) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: <p>Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><u>For diagnosis of multiple myeloma, please answer the following:</u> Is patient going to be using dexamethasone in combination with Xpovio? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Will patient also be treated with Velcade (bortezomib)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is patient's disease refractory to at least one prior therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is patient's disease refractory to no more than three prior therapies? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does patient have systemic light chain amyloidosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does patient have CNS involvement of their disease? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is patient's disease refractory to at least two proteasome inhibitors (such as Ninlaro(ixazomib), Velcade(bortezomib), Kyprolis(carfilzomib))? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit chart documentation.</p> <p>Is patient's disease refractory to at least two immunomodulatory agents (such as Revlimid (lenolidomide), Thalomid (thalidomide), Pomalyst (pomalidomide))? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit chart documentation.</p> <p>Is patient's disease refractory to an anti-CD38 monoclonal antibody (such as Darzalex (daratumumab))? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit chart documentation.</p>		
<p><u>For diagnosis of diffuse large B-cell lymphoma(DLBCL), please answer the following:</u></p> <p>Has patient received at least 2, but no more than 5 previous systemic regimens for the of diffuse large B-cell lymphoma(DLBCL)? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit chart documentation.</p>		





**Xpovio (selinexor)
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

- Does patient have mucosa-associated lymphoid tissue(MALT) lymphoma? Yes No
- Does patient have composite lymphoma(Hodgkin lymphoma+non-Hodgkin lymphoma, or HL+NHL)? Yes No
- Was patient's DLBCL transformed from a disease other than indolent non-Hodgkin lymphoma? Yes No
- Does patient have primary mediastinal(thymic) large B-cell lymphoma(PMBL)? Yes No
- Does patient have a known central nervous system(CNS) lymphoma? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811

